Monotherapy for the treatment of adults w/ locally advanced or metastatic NSCLC w/ activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK).
View Iressa overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food: Swallow whole, or disperse tab in ½ glass of non-carbonated drinking water & stir w/o crushing then, drink immediately. Rinse glass w/ ½ glass of water & drink. Mixt may also be given via a nasogastric or gastrostomy tube.
Assess EGFR mutation when considering gefitinib. Monitor liver function, prothrombin time or INR. Discontinue in ILD; severe changes in liver function; ulcerative keratitis. Caution in patients w/ mild to moderate changes in liver function. Interrupt therapy for up to 14 days in patients w/ poorly tolerated diarrhoea or skin adverse drug reactions. May impair ability to drive & use machines. Pregnancy & lactation.
Sign Out
